ICG132

ICG132 is a dual-targeted chimeric antigen receptor (CAR) T-cell therapy designed to simultaneously target the CD19 and CD20 antigens on the surface of B-cell malignancies. Developed by The First Affiliated Hospital of Xiamen University, this cell therapy is being investigated for the treatment of relapsed or refractory B-cell lymphoma and acute B-lymphoblastic leukemia. By targeting two distinct antigens, ICG132 aims to mitigate the risk of antigen escape, a common mechanism of resistance and relapse in patients treated with single-target CAR-T therapies (such as those targeting CD19 alone). The therapy is typically evaluated in early-phase clinical trials, often in conjunction with other CAR-T products like ICG134.

Other names

CD19/CD20-targeted CAR-TCD19/CD20-targeted chimeric antigen receptor gene-modified T cells